Mammalian Target of Rapamycin As a Target in Hematological Malignancies

Overview

Journal Target Oncol

Specialty Oncology

Date 2011 Apr 19

PMID 21499765

Citations 8

Authors

Kevin R Kelly

Julie H Rowe

Swaminathan Padmanabhan

Steffan T Nawrocki

Jennifer S Carew

Affiliations

Soon will be listed here.

Abstract

The mammalian target of rapamycin (mTOR) regulates protein synthesis in addition to cell growth and cell proliferation. Elucidation of the roles of the phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR pathway in the regulation of the pathogenesis of hematological neoplasms has led to the development and clinical evaluation of agents targeting this pathway for the treatment of leukemia and lymphomas. Clinical trials conducted to date have shown modest responses to mTOR inhibition in patients with various hematological malignancies. Novel agents that simultaneously target mTOR complex 2 (mTORC2) or AKT in addition to mTOR complex 1 (mTORC1) may offer an opportunity to improve therapeutic efficacy.

Citing Articles

L744,832 and Everolimus Induce Cytotoxic and Cytostatic Effects in Non-Hodgkin Lymphoma Cells.

Mendes J, Goncalves A, Alves R, Jorge J, Pires A, Ribeiro A Pathol Oncol Res. 2015; 22(2):301-9.

PMID: 26545383 DOI: 10.1007/s12253-015-9998-4.

Rapamycin restores p14, p15 and p57 expression and inhibits the mTOR/p70S6K pathway in acute lymphoblastic leukemia cells.

Li H, Kong X, Cui G, Ren C, Fan S, Sun L Int J Hematol. 2015; 102(5):558-68.

PMID: 26362858 DOI: 10.1007/s12185-015-1858-1.

Targeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future Perspectives.

Dufour M, Dormond-Meuwly A, Demartines N, Dormond O Cancers (Basel). 2013; 3(2):2478-500.

PMID: 24212820 PMC: 3757428. DOI: 10.3390/cancers3022478.

Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease--a combined tissue microarray, in vitro and in vivo study.

Mark A, Hajdu M, Varadi Z, Sticz T, Nagy N, Csomor J BMC Cancer. 2013; 13:250.

PMID: 23693095 PMC: 3665449. DOI: 10.1186/1471-2407-13-250.

Akt and mTOR in B Cell Activation and Differentiation.

Limon J, Fruman D Front Immunol. 2012; 3:228.

PMID: 22888331 PMC: 3412259. DOI: 10.3389/fimmu.2012.00228.

References

Zent C, LaPlant B, Johnston P, Call T, Habermann T, Micallef I . The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation. Cancer. 2010; 116(9):2201-7. PMC: 2861142. DOI: 10.1002/cncr.25005. View

Pullen N, Thomas G . The modular phosphorylation and activation of p70s6k. FEBS Lett. 1997; 410(1):78-82. DOI: 10.1016/s0014-5793(97)00323-2. View

Ruggero D, Montanaro L, Ma L, Xu W, Londei P, Cordon-Cardo C . The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med. 2004; 10(5):484-6. DOI: 10.1038/nm1042. View

Hsu J, Shi Y, Krajewski S, Renner S, Fisher M, Reed J . The AKT kinase is activated in multiple myeloma tumor cells. Blood. 2001; 98(9):2853-5. DOI: 10.1182/blood.v98.9.2853. View

Chresta C, Davies B, Hickson I, Harding T, Cosulich S, Critchlow S . AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res. 2009; 70(1):288-98. DOI: 10.1158/0008-5472.CAN-09-1751. View

Chen W, Drakos E, Grammatikakis I, Schlette E, Li J, Leventaki V . mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3-mutated acute myeloid leukemia cells. Mol Cancer. 2010; 9:292. PMC: 2993677. DOI: 10.1186/1476-4598-9-292. View

Mita M, Mita A, Chu Q, Rowinsky E, Fetterly G, Goldston M . Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol. 2008; 26(3):361-7. DOI: 10.1200/JCO.2007.12.0345. View

Leseux L, Hamdi S, Al Saati T, Capilla F, Recher C, Laurent G . Syk-dependent mTOR activation in follicular lymphoma cells. Blood. 2006; 108(13):4156-62. DOI: 10.1182/blood-2006-05-026203. View

Hu L, Shi Y, Hsu J, Gera J, Van Ness B, Lichtenstein A . Downstream effectors of oncogenic ras in multiple myeloma cells. Blood. 2003; 101(8):3126-35. DOI: 10.1182/blood-2002-08-2640. View

10.

Chapuis N, Tamburini J, Green A, Vignon C, Bardet V, Neyret A . Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clin Cancer Res. 2010; 16(22):5424-35. DOI: 10.1158/1078-0432.CCR-10-1102. View

11.

Mirza A, Kohn A, Roth R, McMahon M . Oncogenic transformation of cells by a conditionally active form of the protein kinase Akt/PKB. Cell Growth Differ. 2000; 11(6):279-92. View

12.

Shayesteh L, Lu Y, Kuo W, Baldocchi R, Godfrey T, Collins C . PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet. 1999; 21(1):99-102. DOI: 10.1038/5042. View

13.

Rizzieri D, Feldman E, Dipersio J, Gabrail N, Stock W, Strair R . A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2008; 14(9):2756-62. DOI: 10.1158/1078-0432.CCR-07-1372. View

14.

Decker T, Hipp S, Ringshausen I, Bogner C, Oelsner M, Schneller F . Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. Blood. 2002; 101(1):278-85. DOI: 10.1182/blood-2002-01-0189. View

15.

Powers T, Walter P . Regulation of ribosome biogenesis by the rapamycin-sensitive TOR-signaling pathway in Saccharomyces cerevisiae. Mol Biol Cell. 1999; 10(4):987-1000. PMC: 25225. DOI: 10.1091/mbc.10.4.987. View

16.

Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X . TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell. 2006; 126(5):955-68. DOI: 10.1016/j.cell.2006.06.055. View

17.

Xu Q, Simpson S, Scialla T, Bagg A, Carroll M . Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood. 2003; 102(3):972-80. DOI: 10.1182/blood-2002-11-3429. View

18.

Recher C, Beyne-Rauzy O, Demur C, Chicanne G, Dos Santos C, Mas V . Antileukemic activity of rapamycin in acute myeloid leukemia. Blood. 2004; 105(6):2527-34. DOI: 10.1182/blood-2004-06-2494. View

19.

Kharas M, Deane J, Wong S, OBosky K, Rosenberg N, Witte O . Phosphoinositide 3-kinase signaling is essential for ABL oncogene-mediated transformation of B-lineage cells. Blood. 2004; 103(11):4268-75. DOI: 10.1182/blood-2003-07-2193. View

20.

Long X, Lin Y, Ortiz-Vega S, Yonezawa K, Avruch J . Rheb binds and regulates the mTOR kinase. Curr Biol. 2005; 15(8):702-13. DOI: 10.1016/j.cub.2005.02.053. View